Cohort1: Inclisiran_Day 1 and Day 90
|
Administration route |
subcutaneous injection |
Dosage |
Inclisiran sodium, 300 mg, Day 1 and Day 90 |
Pts |
37 |
Age |
Adult, Older_Adult |
Outcome |
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150:2.39 |
Adverse reactions |
0/37(All-cause mortality); 2/37(General disorders; Infections and infestations; Neoplasms benign, malignant and unspecified(incl cysts and polyps)) |
References |
PMID:
33990512
|
|
Cohort2: Placebo
|
Administration route |
subcutaneous injection |
Dosage |
placebos, 300 mg, Day 1 and Day 90 |
Pts |
19 |
Age |
Adult, Older_Adult |
Outcome |
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150:0.70 |
Adverse reactions |
0/19(All-cause mortality); 1/19(Social circumstances) |
References |
PMID:
33990512
|
|
Cohort3: Inclisiran_Day 270, Day 450 and Day 630
|
Administration route |
subcutaneous injection |
Dosage |
Inclisiran sodium, 300 mg, Day 270, Day 450 and Day 630 |
Pts |
53 |
Age |
Adult, Older_Adult |
Adverse reactions |
3/53(All-cause mortality); 11/53(Cardiac disorders; General disorders; Hepatobiliary disorders; Infections and infestations; Injury, poisoning and procedural complications; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Renal and urinary disorders; Reproductive system and breast disorders; Respiratory, thoracic and mediastinal disorders) |
References |
PMID:
33990512
|
|